Le Joncour, Vadim; Martins, Ana; Puhka, Maija; Isola, Jorma; Salmikangas, Marko; Laakkonen, Pirjo; Joensuu, Heikki; Barok, Mark;,
A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine., Molecular cancer therapeutics Vol.18, 2019
Czardybon, W., Windak, R., Golas, A., Galezowski, M., Sabiniarz, A., Dolata, I., . . . Brzozka, K. (2018),
A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia., Oncotarget, 9(24), 16917-16931. doi:10.18632/oncotarget.24747 [doi]
Landolina N, Zaffran I, Smiljkovic D, Serrano-Candelas E, Schmiedel D, Friedman S, Arock M, Hartmann K, Pikarsky E, Mandelboim O, Martin M, Valent P, Levi-Schaffer F.,
Activation of Siglec-7 results in inhibition of in vitro and in vivo growth of human mast cell leukemia cells, Pharmacol Res. 2020 Aug;158:104682. doi: 10.1016/j.phrs.2020.104682. Epub 2020 Feb 5.
Kelly, R. K., Olson, D. L., Sun, Y., Wen, D., Wortham, K. A., Antognetti, G., . . . Sanicola, M. (2011),
An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for cripto positive tumours., . European Journal of Cancer (Oxford, England : 1990), 47(11), 1736-1746. doi:10.1016/j.ejca.2011.02.023 [doi]
Urbinati, G., Ali, H. M., Rousseau, Q., Chapuis, H., Desmaele, D., Couvreur, P., & Massaad-Massade, L. (2015).,
Antineoplastic effects of siRNA against TMPRSS2-ERG junction oncogene in prostate cancer., PloS One, 10(5), e0125277. doi:10.1371/journal.pone.0125277 [doi]
Egberts, J. H., Cloosters, V., Noack, A., Schniewind, B., Thon, L., Klose, S., . . . Trauzold, A.,
Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis., Cancer Research, 68(5), 1443-1450. doi:10.1158/0008-5472.CAN-07-5704 [doi]
Zhao, Ning; Peacock, Stephanie O; Lo, Chen Hao; Heidman, Laine M; Rice, Meghan A; Fahrenholtz, Cale D; Greene, Ann M; Magani, Fiorella;,
Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer., Science translational medicine Vol.11, 2019
Wei J, Yin L, Li J, Wang J, Pu T, Duan P, Lin TP, Gao AC, Wu BJ.,
Bidirectional Cross-talk between MAOA and AR Promotes Hormone-Dependent and Castration-Resistant Prostate Cancer, Cancer Res. 2021 Aug 15;81(16):4275-4289. doi: 10.1158/0008-5472.CAN-21-0198. Epub 2021 Jun 24.
Biswas N, Abu Ammar A, Frušić-Zlotkin M, Adi-Hen N, Lehman-Katabi Y, Levi-Kalisman Y, Nassar T, Benita S.,
Biodistribution and efficacy of the anticancer drug, oxaliplatin palmitate acetate, in mice, Int J Pharm. 2021 Jul 15;604:120740. doi: 10.1016/j.ijpharm.2021.120740. Epub 2021 May 29.
Parhi L, Alon-Maimon T, Sol A, Nejman D, Shhadeh A, Fainsod-Levi T, Yajuk O, Isaacson B, Abed J, Maalouf N, Nissan A, Sandbank J, Yehuda-Shnaidman E, Ponath F, Vogel J, Mandelboim O, Granot Z, Straussman R, Bachrach G.,
Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression, Nat Commun. 2020 Jun 26;11(1):3259. doi: 10.1038/s41467-020-16967-2.
von Karstedt, S., Conti, A., Nobis, M., Montinaro, A., Hartwig, T., Lemke, J., . . . Walczak, H. (2015).,
Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis., Cancer Cell, 27(4), 561-573. doi:10.1016/j.ccell.2015.02.014 [doi]
Pesakhov, S., Nachliely, M., Barvish, Z., Aqaqe, N., Schwartzman, B., Voronov, E., . . . Danilenko, M. (2016),
Cancer-selective cytotoxic Ca2+ overload in acute myeloid leukemia cells and attenuation of disease progression in mice by synergistically acting polyphenols curcumin and carnosic acid, Oncotarget, 7(22), 31847-31861. doi:10.18632/oncotarget.7240 [doi]
Assimon VA, Tang Y, Vargas JD, Lee GJ, Wu ZY, Lou K, Yao B, Menon MK, Pios A, Perez KC, Madriaga A, Buchowiecki PK, Rolfe M, Shawver L, Jiao X, Le Moigne R, Zhou HJ, Anderson DJ,
CB-6644 Is a Selective Inhibitor of the RUVBL1/2 Complex with Anticancer Activity., ACS Chem Biol. 2019 Feb 15;14(2):236-244.
Rakhmilevich, A. L., Buhtoiarov, I. N., Malkovsky, M., & Sondel, P. M. (2008).,
CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors., Cancer Immunology, Immunotherapy : CII, 57(8), 1151-1160. doi:10.1007/s00262-007-0447-4 [doi]
Hurley RM, McGehee CD, Nesic K, Correia C, Weiskittel TM, Kelly RL, Venkatachalam A, Hou X, Pathoulas NM, Meng XW, Kondrashova O, Radke MR, Schneider PA, Flatten KS, Peterson KL, Becker MA, Wong EM, Southey MS, Dobrovic A, Lin KK, Harding TC, McNeish I, Ross CA, Wagner JM, Wakefield MJ, Scott CL, Haluska P, Wahner Hendrickson AE, Karnitz LM, Swisher EM, Li H, Weroha SJ, Kaufmann SH.,
Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance, NAR Cancer. 2021 Jul 9;3(3):zcab028. doi: 10.1093/narcan/zcab028. eCollection 2021 Sep.
Sobot, D., Mura, S., Rouquette, M., Vukosavljevic, B., Cayre, F., Buchy, E., . . . Couvreur, P. (2017).,
Circulating lipoproteins: A trojan horse guiding squalenoylated drugs to LDL-accumulating cancer cells., Molecular Therapy : The Journal of the American Society of Gene Therapy, 25(7), 1596-1605. doi:S1525-0016(17)30234-4 [pii]
Kaeopookum, Piriya; Petrik, Milos; Summer, Dominik; Klinger, Maximilian; Zhai, Chuangyan; Rangger, Christine; Haubner, Roland; Haas, Hubertus; Hajduch, Marian; Decristoforo, Clemens;,
Comparison of 68Ga-labeled RGD mono- and multimers based on a clickable siderophore-based scaffold., Nuclear medicine and biology Vol.78-79,
Liu D, Hou X, Wu W, Zanfagnin V, Li Y, Correia C, Zhao Z, Zhao C, Liu Z, Zhang T, Fang Z, Wang H, Xu C, Weroha SJ, Kaufmann SH, Dai H.,
Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer, Cell Death Dis. 2021 Aug 12;12(8):789. doi: 10.1038/s41419-021-04073-0.
Stangl, S., Wortmann, A., Guertler, U., & Multhoff, G. (2006).,
Control of metastasized pancreatic carcinomas in SCID/beige mice with human IL-2/TKD-activated NK cells., Journal of Immunology (Baltimore, Md.: 1950), 176(10), 6270-6276. doi:176/10/6270 [pii]
Glaser, G., Weroha, S. J., Becker, M. A., Hou, X., Enderica-Gonzalez, S., Harrington, S. C., & Haluska, P. (2015).,
Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft., PloS One, 10(5), e0126867. doi:10.1371/journal.pone.0126867 [doi]
Bartalucci, N., Tozzi, L., Bogani, C., Martinelli, S., Rotunno, G., Villeval, J. L., & Vannucchi, A. M. (2013).,
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms., Journal of Cellular and Molecular Medicine, 17(11), 1385-1396. doi:10.1111/jcmm.12162 [doi]
Egberts, J. H., Schniewind, B., Patzold, M., Kettler, B., Tepel, J., Kalthoff, H., & Trauzold, A. (2008).,
Dexamethasone reduces tumor recurrence and metastasis after pancreatic tumor resection in SCID mice., Cancer Biology & Therapy, 7(7), 1044-1050. doi:6099 [pii]
Nachliely M, Trachtenberg A, Khalfin B, Nalbandyan K, Cohen-Lahav M, Yasuda K, Sakaki T, Kutner A, Danilenko M.,
Dimethyl fumarate and vitamin D derivatives cooperatively enhance VDR and Nrf2 signaling in differentiating AML cells in vitro and inhibit leukemia progression in a xenograft mouse model., . J Steroid Biochem Mol Biol. 2019 Apr;188:8-16
Hiriyan, J., Shivarudraiah, P., Gavara, G., Annamalai, P., Natesan, S., Sambasivam, G., & Sukumaran, S. K. (2015).,
Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models, Anticancer Research, 35(1), 229-237. doi:35/1/229 [pii]
Fonti, Claire; Saumet, Anne; Abi-Khalil, Amanda; Orsetti, Béatrice; Cleroux, Elouan; Bender, Ambre; Dumas, Michael; Schmitt, Emeline; Colinge, Jacques; Jacot, William; Weber, Michael; Sardet, Claude; du Manoir, Stanislas; Theillet, Charles;,
Distinct oncogenes drive different genome and epigenome alterations in human mammary epithelial cells, International journal of cancer Vol.145, 2019
Key, J., Aryal, S., Gentile, F., Ananta, J. S., Zhong, M., Landis, M. D., & Decuzzi, P. (2013).,
Engineering discoidal polymeric nanoconstructs with enhanced magneto-optical properties for tumor imaging, Biomaterials, 34(21), 5402-5410. doi:10.1016/j.biomaterials.2013.03.078 [doi]
Natoni, A., Smith, T. A. G., Keane, N., McEllistrim, C., Connolly, C., Jha, A., . . . O'Dwyer, M. E. (2017).,
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271., Leukemia, 31(12), 2642-2651. doi:10.1038/leu.2017.123 [doi]
De Thaye E, Van de Vijver K, Van der Meulen J, Taminau J, Wagemans G, Denys H, Van Dorpe J, Berx G, Ceelen W, Van Bocxlaer J, De Wever O.,
Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma, Sci Rep. 2020 Apr 21;10(1):6688. doi: 10.1038/s41598-020-63738-6.
Naumann, C. M., Sperveslage, J., Hamann, M. F., Leuschner, I., Weder, L., Al-Najar, A. A., . . . Kalthoff, H. (2012).,
Establishment and characterization of primary cell lines of squamous cell carcinoma of the penis and its metastasis., The Journal of Urology, 187(6), 2236-2242. doi:10.1016/j.juro.2012.01.035 [doi]
Srivastava, Swati; Nataraj, Nishanth Belugali; Sekar, Arunachalam; Ghosh, Soma; Bornstein, Chamutal; Drago-Garcia, Diana; Roth, Lee; Romaniello, Donatella; Marrocco, Ilaria; David, Eyal; Gilad, Yuval; Lauriola, Mattia; Rotkopf, Ron; Kimchi, Adi; Haga, Yuya; Tsutsumi, Yasuo; Mirabeau, Olivier; Surdez, Didier; Zinovyev, Andrei; Delattre, Olivier; Kovar, Heinrich; Amit, Ido; Yarden, Yosef;,
ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma, Cell reports Vol.29, 2019
Owonikoko, Taofeek K; Zhang, Guojing; Lallani, Shenila B; Chen, Zhengjia; Martinson, Deborah E; Khuri, Fadlo R; Lonial, Sagar; Marcus, Adam; Sun, Shi-Yong;,
Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models., PloS one Vol.14, 2019
Bailey, K. M., Cornnell, H. H., Ibrahim-Hashim, A., Wojtkowiak, J. W., Hart, C. P., Zhang, X., . . . Gillies, R. J. (2014).,
Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer., PloS One, 9(12), e113586. doi:10.1371/journal.pone.0113586 [doi]
Cody, J. J., Rivera, A. A., Lyons, G. R., Yang, S. W., Wang, M., Ashley, J. W., . . . Douglas, J. T. (2013).,
Expression of osteoprotegerin from a replicating adenovirus inhibits the progression of prostate cancer bone metastases in a murine model., Laboratory Investigation; a Journal of Technical Methods and Pathology, 93(3), 268-278. doi:10.1038/labinvest.2012.179 [doi]
Ronca R, Ghedini GC, Maccarinelli F, Sacco A, Locatelli SL, Foglio E, Taranto S, Grillo E, Matarazzo S, Castelli R, Paganini G, Desantis V, Cattane N, Cattaneo A, Mor M, Carlo-Stella C, Belotti A, Roccaro AM, Presta M, Giacomini A.,
FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress, Cancer Res. 2020 Jun 1;80(11):2340-2354. doi: 10.1158/0008-5472.CAN-19-2714. Epub 2020 Feb 24.
Dahis, D., Azagury, D.M., Obeid, F., Dion, M.Z., Cryer, A.M., Riquelme, M.A., Dosta, P., Abraham, A.W., Gavish, M., Artzi, N. and Shamay, Y.,
Focused Ultrasound Enhances Brain Delivery of Sorafenib Nanoparticles, Advanced NanoBiomed Research, 3(2), p.2200142.
Kurdow, R., Boehle, A. S., Haye, S., Boenicke, L., Schniewind, B., Dohrmann, P., & Kalthoff, H. (2002).,
Ganciclovir prodrug therapy is effective in a murine xenotransplant model of human lung cancer, The Annals of Thoracic Surgery, 73(3), 905-910.
von Forstner, C., Egberts, J. H., Ammerpohl, O., Niedzielska, D., Buchert, R., Mikecz, P., . . . Brenner, W. (2008).,
Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer., Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 49(8), 1362-1370. doi:10.2967/jnumed.107.050021 [doi]
Ding, H., Peterson, K. L., Correia, C., Koh, B., Schneider, P. A., Nowakowski, G. S., & Kaufmann, S. H. (2017).,
Histone deacetylase inhibitors interrupt HSP90*RASGRP1 and HSP90*CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells, Leukemia, 31(7), 1593-1602. doi:10.1038/leu.2016.357 [doi]
Debeb, B. G., Lacerda, L., Xu, W., Larson, R., Solley, T., Atkinson, R., . . . Woodward, W. A. (2012).,
Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/beta-catenin signaling., Stem Cells (Dayton, Ohio), 30(11), 2366-2377. doi:10.1002/stem.1219 [doi]
Gatto, F., Redaelli, D., Salvade, A., Marzorati, S., Sacchetti, B., Ferina, C., . . . Serafini, M. (2012).,
Hurler disease bone marrow stromal cells exhibit altered ability to support osteoclast formation., Stem Cells and Development, 21(9), 1466-1477. doi:10.1089/scd.2011.0555 [doi]
Lipnik, K., Greco, O., Scott, S., Knapp, E., Mayrhofer, E., Rosenfellner, D., . . . Hohenadl, C. (2006).,
Hypoxia- and radiation-inducible, breast cell-specific targeting of retroviral vectors, Virology, 349(1), 121-133. doi:S0042-6822(05)00851-2 [pii]
Feng, Yongmei; Sessions, E Hampton; Zhang, Fan; Ban, Fuqiang; Placencio-Hickok, Veronica; Ma, Chen-Ting; Zeng, Fu-Yue; Pass, Ian; Terry, David B; Cadwell, Gregory; Bankston, Laurie A; Liddington, Robert C; Chung, Thomas D Y; Pinkerton, Anthony B; Sergienko, Eduard; Gleave, Martin; Bhowmick, Neil A; Jackson, Michael R; Cherkasov, Artem; Ronai, Zeev A;,
Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells., Cancer letters Vol.449, 2019
Lin ZP, Al Zouabi NN, Xu ML, Bowen NE, Wu TL, Lavi ES, Huang PH, Zhu YL, Kim B, Ratner ES.,
In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer, Sci Rep. 2021 Apr 13;11(1):8042. doi: 10.1038/s41598-021-87325-5.
Potter, D. S., Galvin, M., Brown, S., Lallo, A., Hodgkinson, C. L., Blackhall, F., . . . Dive, C. (2016).,
Inhibition of PI3K/BMX cell survival pathway sensitizes to BH3 mimetics in SCLC, Molecular Cancer Therapeutics, 15(6), 1248-1260. doi:10.1158/1535-7163.MCT-15-0885 [doi]
Gill, S. E., Zhang, Q., Keeney, G. L., Cliby, W. A., & Weroha, S. J. (2017).,
Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR, Oncotarget, 8(49), 85214-85223. doi:10.18632/oncotarget.19620 [doi]
Gou X, Kim BJ, Anurag M, Lei JT, Young MN, Holt MV, Fandino D, Vollert CT, Singh P, Alzubi MA, Malovannaya A, Dobrolecki LE, Lewis MT, Li S, Foulds CE, Ellis MJ.,
Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer., Cancer Res. 2023 Oct 2;83(19):3237-3251. doi: 10.1158/0008-5472.CAN-22-3484.
Stein, U., Walther, W., Arlt, F., Schwabe, H., Smith, J., Fichtner, I., . . . Schlag, P. M. (2009).,
MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis, . Nature Medicine, 15(1), 59-67. doi:10.1038/nm.1889 [doi]
Wang, Wei; Shen, Tao; Dong, Bingning; Creighton, Chad J; Meng, Yanling; Zhou, Wolong; Shi, Qing; Zhou, Hao; Zhang, Yinjie; Moore, David D; Yang, Feng,
MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling., The Journal of clinical investigation Vol.129, 2019
Shen T, Wang W, Zhou W, Coleman I, Cai Q, Dong B, Ittmann MM, Creighton CJ, Bian Y, Meng Y, Rowley DR, Nelson PS, Moore DD, Yang F.,
MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT, J Clin Invest. 2021 Feb 15;131(4):e135465. doi: 10.1172/JCI135465.
Satpathy S, Jaehnig EJ, Krug K, Kim BJ, Saltzman AB, Chan DW, Holloway KR, Anurag M, Huang C, Singh P, Gao A, Namai N, Dou Y, Wen B, Vasaikar SV, Mutch D, Watson MA, Ma C, Ademuyiwa FO, Rimawi MF, Schiff R, Hoog J, Jacobs S, Malovannaya A, Hyslop T, Clauser KR, Mani DR, Perou CM, Miles G, Zhang B, Gillette MA, Carr SA, Ellis MJ.,
Microscaled proteogenomic methods for precision oncology, Nat Commun. 2020 Jan 27;11(1):532. doi: 10.1038/s41467-020-14381-2.
van de Ven, A. L., Abdollahi, B., Martinez, C. J., Burey, L. A., Landis, M. D., Chang, J. C., . . . Frieboes, H. B. (2013).,
Modeling of nanotherapeutics delivery based on tumor perfusion., New Journal of Physics, 15, 55004. doi:10.1088/1367-2630/15/5/055004 [doi]
van Brussel, A. S., Adams, A., Vermeulen, J. F., Oliveira, S., van der Wall, E., Mali, W. P., . . . van Bergen En Henegouwen, P. M. (2013),
Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast., Breast Cancer Research and Treatment, 140(2), 263-272. doi:10.1007/s10549-013-2635-6 [doi]
Huang D, Chowdhury S, Wang H, Savage SR, Ivey RG, Kennedy JJ, Whiteaker JR, Lin C, Hou X, Oberg AL, Larson MC, Eskandari N, Delisi DA, Gentile S, Huntoon CJ, Voytovich UJ, Shire ZJ, Yu Q, Gygi SP, Hoofnagle AN, Herbert ZT, Lorentzen TD, Calinawan A, Karnitz LM, Weroha SJ, Kaufmann SH, Zhang B, Wang P, Birrer MJ, Paulovich AG.,
Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer, Cell Rep Med. 2021 Dec 21;2(12):100471. doi: 10.1016/j.xcrm.2021.100471. eCollection 2021 Dec 21.
Fukumura K, Malgulwar PB, Fischer GM, Hu X, Mao X, Song X, Hernandez SD, Zhang XH, Zhang J, Parra ER, Yu D, Debeb BG, Davies MA, Huse JT.,
Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis, Acta Neuropathol. 2021 Feb;141(2):303-321. doi: 10.1007/s00401-020-02256-1. Epub 2021 Jan 4.
Vermeulen, J. F., van Brussel, A. S., Adams, A., Mali, W. P., van der Wall, E., van Diest, P. J., & Derksen, P. W. (2013).,
Near-infrared fluorescence molecular imaging of ductal carcinoma in situ with CD44v6-specific antibodies in mice: A preclinical study., Molecular Imaging and Biology : MIB : The Official Publication of the Academy of Molecular Imaging, 15(3), 290-298. doi:10.1007/s11307-012-0605-8 [doi]
Veeraraghavan J, Gutierrez C, Sethunath V, Mehravaran S, Giuliano M, Shea MJ, Mitchell T, Wang T, Nanda S, Pereira R, Davis R, Goutsouliak K, Qin L, De Angelis C, Diala I, Lalani AS, Nagi C, Hilsenbeck SG, Rimawi MF, Osborne CK, Schiff R.,
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models, NPJ Breast Cancer. 2021 May 27;7(1):63. doi: 10.1038/s41523-021-00274-0.
Zheng ZY, Anurag M, Lei JT, Cao J, Singh P, Peng J, Kennedy H, Nguyen NC, Chen Y, Lavere P, Li J, Du XH, Cakar B, Song W, Kim BJ, Shi J, Seker S, Chan DW, Zhao GQ, Chen X, Banks KC, Lanman RB, Shafaee MN, Zhang XH, Vasaikar S, Zhang B, Hilsenbeck SG, Li W, Foulds CE, Ellis MJ, Chang EC.,
Neurofibromin Is an Estrogen Receptor-Îą Transcriptional Co-repressor in Breast Cancer, Cancer Cell. 2020 Mar 16;37(3):387-402.e7. doi: 10.1016/j.ccell.2020.02.003. Epub 2020 Mar 5.
Abelson, S., Shamai, Y., Berger, L., Skorecki, K., & Tzukerman, M. (2013).,
Niche-dependent gene expression profile of intratumoral heterogeneous ovarian cancer stem cell populations., PloS One, 8(12), e83651. doi:10.1371/journal.pone.0083651 [doi]
Torres, Diogo; Hou, Xiaonan; Bale, Laurie; Heinzen, Ethan P; Maurer, Matthew J; Zanfagnin, Valentina; Oberg, Ann L; Conover, Cheryl; Weroha, S John,
Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A, PloS one Vol.14, 2019
Sheng Q, D'Alessio JA, Menezes DL, Karim C, Tang Y, Tam A, Clark S, Ying C, Connor A, Mansfield KG, Rondeau JM, Ghoddusi M, Geyer FC, Gu J, McLaughlin ME, Newcombe R, Elliot G, Tschantz WR, Lehmann S, Fanton CP, Miller K, Huber T, Rendahl KG, Jeffry U, Pryer NK, Lees E, Kwon P, Abraham JA, Damiano JS, Abrams TJ.,
PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing Malignancies, Mol Cancer Ther. 2021 Jul;20(7):1270-1282. doi: 10.1158/1535-7163.MCT-20-0708. Epub 2021 Apr 20.
Sasikumar PG, Sudarshan NS, Adurthi S, Ramachandra RK, Samiulla DS, Lakshminarasimhan A, Ramanathan A, Chandrasekhar T, Dhudashiya AA, Talapati SR, Gowda N, Palakolanu S, Mani J, Srinivasrao B, Joseph D, Kumar N, Nair R, Atreya HS, Gowda N, Ramachandra M.,
PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy, Commun Biol. 2021 Jun 8;4(1):699. doi: 10.1038/s42003-021-02191-1.
Ronca R, Taranto S, Corsini M, Tobia C, Ravelli C, Rezzola S, Belleri M, De Cillis F, Cattaneo A, Presta M, Giacomini A.,
Pentraxin 3 Inhibits the Angiogenic Potential of Multiple Myeloma Cells, Cancers (Basel). 2021 May 8;13(9):2255. doi: 10.3390/cancers13092255.
Reka, A. K., Kurapati, H., Narala, V. R., Bommer, G., Chen, J., Standiford, T. J., & Keshamouni, V. G. (2010).,
Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition., Molecular Cancer Therapeutics, 9(12), 3221-3232. doi:10.1158/1535-7163.MCT-10-0570 [doi]
Hong, S. H., Youbi, S. E., Hong, S. P., Kallakury, B., Monroe, P., Erkizan, H. V., . . . Toretsky, J. A. (2014).,
Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in ewing sarcoma, Oncotarget, 5(2), 338-350. doi:1495 [pii]
Davila-Gonzalez, D., Choi, D. S., Rosato, R. R., Granados-Principal, S. M., Kuhn, J. G., Li, W. F., . . . Chang, J. C. (2018).,
Pharmacological inhibition of NOS activates ASK1/JNK pathway augmenting docetaxel-mediated apoptosis in triple-negative breast cancer., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 24(5), 1152-1162. doi:10.1158/1078-0432.CCR-17-1437 [doi]
Zhao, N., Cao, J., Xu, L., Tang, Q., Dobrolecki, L. E., Lv, X., . . . Chen, X. (2018),
Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer., The Journal of Clinical Investigation, 128(4), 1283-1299. doi:10.1172/JCI95873 [doi]
Colon-Otero G, Zanfagnin V, Hou X, Foster NR, Asmus EJ, Wahner Hendrickson A, Jatoi A, Block MS, Langstraat CL, Glaser GE, Dinh TA, Robertson MW, Camoriano JK, Butler KA, Copland JA, Weroha SJ.,
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers, ESMO Open. 2020 Oct;5(5):e000926. doi: 10.1136/esmoopen-2020-000926.
Santiago-O'Farrill JM, Weroha SJ, Hou X, Oberg AL, Heinzen EP, Maurer MJ, Pang L, Rask P, Amaravadi RK, Becker SE, Romero I, Rubio MJ, Matias-Guiu X, Santacana M, Llombart-Cussac A, Poveda A, Lu Z, Bast RC Jr.,
Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models, Cancer. 2020 Feb 15;126(4):894-907. doi: 10.1002/cncr.32600. Epub 2019 Nov 12.
Ingallina, C., Costa, P. M., Ghirga, F., Klippstein, R., Wang, J. T., Berardozzi, S., . . . Al-Jamal, K. T. (2017).,
Polymeric glabrescione B nanocapsules for passive targeting of hedgehog-dependent tumor therapy in vitro., Nanomedicine (London, England), 12(7), 711-728. doi:10.2217/nnm-2016-0388 [doi]
Schott, A. F., Landis, M. D., Dontu, G., Griffith, K. A., Layman, R. M., Krop, I., . . . Chang, J. C. (2013),
Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors, Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 19(6), 1512-1524. doi:10.1158/1078-0432.CCR-11-3326 [doi]
Abrams, T., Connor, A., Fanton, C., Cohen, S. B., Huber, T., Miller, K., . . . Schleyer, S. C. (2018),
Preclinical antitumor activity of a novel anti-c-KIT antibody-drug conjugate against mutant and wild-type c-KIT-positive solid tumors, Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 24(17), 4297-4308. doi:10.1158/1078-0432.CCR-17-3795 [doi]
Janku F, Han SW, Doi T, Amatu A, Ajani JA, Kuboki Y, Cortez A, Cellitti SE, Mahling PC, Subramanian K, Schoenfeld HA, Choi SM, Iaconis LA, Lee LH, Pelletier MR, Dranoff G, Askoxylakis V, Siena S.,
Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies, Cancer Immunol Res. 2022 Dec 2;10(12):1441-1461. doi: 10.1158/2326-6066.CIR-21-0722.
Lee, F. Y., Smykla, R., Johnston, K., Menard, K., McGlinchey, K., Peterson, R. W., . . . Kramer, R. (2009,
Preclinical efficacy spectrum and pharmacokinetics of ixabepilone, Cancer Chemotherapy and Pharmacology, 63(2), 201-212. doi:10.1007/s00280-008-0727-5 [doi]
Kim BJ, Zheng ZY, Lei JT, Holt MV, Chen A, Peng J, Fandino D, Singh P, Kennedy H, Dou Y, Chica-Parrado MDR, Bikorimana E, Ye D, Wang Y, Hanker AB, Mohamed N, Hilsenbeck SG, Lim B, Asirvatham JR, Sreekumar A, Zhang B, Miles G, et al.,
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment., Cancer Res Commun. 2023 Jul 26;3(7):1366-1377. doi: 10.1158/2767-9764.CRC-23-0044. eCollection 2023 Jul.
Huang, K. L., Li, S., Mertins, P., Cao, S., Gunawardena, H. P., Ruggles, K. V., . . . Ding, L. (2017).,
Proteogenomic integration reveals therapeutic targets in breast cancer xenografts, Nature Communications, 8, 14864. doi:10.1038/ncomms14864 [doi]
Goswami, M. T., Reka, A. K., Kurapati, H., Kaza, V., Chen, J., Standiford, T. J., & Keshamouni, V. G. (2015),
Regulation of complement-dependent cytotoxicity by TGF-beta-induced epithelial-mesenchymal transition., Oncogene, doi:10.1038/onc.2015.258 [doi]
McDaid, William J; Greene, Michelle K; Johnston, Michael C; Pollheimer, Ellen; Smyth, Peter; McLaughlin, Kirsty; Van Schaeybroeck, Sandra; Straubinger, Robert M; Longley, Daniel B; Scott, Christopher J;,
Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours, Nanoscale Vol.11, 2019
Speyer, C. L., Bukhsh, M. A., Jafry, W. S., Sexton, R. E., Bandyopadhyay, S., & Gorski, D. H. (2017).,
Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer., Breast Cancer Research and Treatment, 166(2), 407-419. doi:10.1007/s10549-017-4435-x [doi]
Miron, T., Wilchek, M., Shvidel, L., Berrebi, A., & Arditti, F. D. (2012).,
S-allyl derivatives of 6-mercaptopurine are highly potent drugs against human B-CLL through synergism between 6-mercaptopurine and allicin., Leukemia Research, 36(12), 1536-1540. doi:10.1016/j.leukres.2012.08.023 [doi]
Rzymski, T., Mikula, M., Zylkiewicz, E., Dreas, A., Wiklik, K., Golas, A., . . . Brzozka, K. (2017).,
SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains., Oncotarget, 8(20), 33779-33795. doi:10.18632/oncotarget.16810 [doi]
Catalano A, Adlesic M, Kaltenbacher T, Klar RFU, Albers J, Seidel P, Brandt LP, Hejhal T, Busenhart P, Röhner N, Zodel K, Fritsch K, Wild PJ, Duyster J, Fritsch R, Brummer T, Frew IJ.,
Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition, Cancers (Basel). 2021 Apr 13;13(8):1852. doi: 10.3390/cancers13081852.
Reddy TP, Choi DS, Anselme AC, Qian W, Chen W, Lantto J, Horak ID, Kragh M, Chang JC, Rosato RR.,
Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs, Breast Cancer Res. 2020 May 15;22(1):48. doi: 10.1186/s13058-020-01280-z.
Schenk MW, Humphrey S, Hossain ASMM, Revill M, Pearsall S, Lallo A, Brown S, Bratt S, Galvin M, Descamps T, Zhou C, Pearce SP, Priest L, Greenhalgh M, Chaturvedi A, Kerr A, Blackhall F, Dive C, Frese KK.,
Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer, Nat Commun. 2021 Nov 17;12(1):6652. doi: 10.1038/s41467-021-26823-6.
Li, X., Wu, J. B., Li, Q., Shigemura, K., Chung, L. W., & Huang, W. C. (2016).,
SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-myc in prostate cancer, Lee, F. Y., Smykla, R., Johnston, K., Menard, K., McGlinchey, K., Peterson, R. W., . . . Kramer, R. (2009
Egberts, J. H., Schniewind, B., Sipos, B., Hinz, S., Kalthoff, H., & Tepel, J. (2007).,
Superiority of extended neoadjuvant chemotherapy with gemcitabine in pancreatic cancer: A comparative analysis in a clinically adapted orthotopic xenotransplantation model in SCID beige mice., Cancer Biology & Therapy, 6(8), 1227-1232. doi:4414 [pii]
Vallejo-Diaz, J., Olazabal-Moran, M., Cariaga-Martinez, A. E., Pajares, M. J., Flores, J. M., Pio, R., . . . Carrera, A. C. (2016),
Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma., Oncotarget, 7(51), 85063-85078. doi:10.18632/oncotarget.13195 [doi]
Schwarzer A, Oliveira M, Kleppa MJ, Slattery SD, Anantha A, Cooper A, Hannink M, Schambach A, Dörrie A, Kotlyarov A, Gaestel M, Hembrough T, Levine J, Luther M, Stocum M, Stiles L, Weinstock DM, Liesa M, Kostura MJ.,
Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1., Mol Cancer Ther. 2023 Nov 1;22(11):1290-1303. doi: 10.1158/1535-7163.MCT-22-0718.
Harris, Faye R; Zhang, Piyan; Yang, Lin; Hou, Xiaonan; Leventakos, Konstantinos; Weroha, Saravut J; Vasmatzis, George; Kovtun, Irina V;,
Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy., Molecular oncology Vol.13, 2019
Guerra-Rebollo, Marta; Garrido, Cristina; Sánchez-Cid, Lourdes; Soler-Botija, Carolina; Meca-Cortés, Oscar; Rubio, Nuria; Blanco, Jerónimo;,
Targeting of replicating CD133 and OCT4/SOX2 expressing glioma stem cells selects a cell population that reinitiates tumors upon release of therapeutic pressure., Scientific reports Vol.9, 2019
Xu, W., Lacerda, L., Debeb, B. G., Atkinson, R. L., Solley, T. N., Li, L., . . . Woodward, W. A. (2013).,
The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer., PloS One, 8(8), e71508. doi:10.1371/journal.pone.0071508 [doi]
Bado IL, Zhang W, Hu J, Xu Z, Wang H, Sarkar P, Li L, Wan YW, Liu J, Wu W, Lo HC, Kim IS, Singh S, Janghorban M, Muscarella AM, Goldstein A, Singh P, Jeong HH, Liu C, Schiff R, Huang S, Ellis MJ, Gaber MW, Gugala Z, Liu Z, Zhang XH.,
The bone microenvironment increases phenotypic plasticity of ER(+) breast cancer cells, Dev Cell. 2021 Apr 19;56(8):1100-1117.e9. doi: 10.1016/j.devcel.2021.03.008.
Serebrenik AA, Argyris PP, Jarvis MC, Brown WL, Bazzaro M, Vogel RI, Erickson BK, Lee SH, Goergen KM, Maurer MJ, Heinzen EP, Oberg AL, Huang Y, Hou X, Weroha SJ, Kaufmann SH, Harris RS.,
The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer, Clin Cancer Res. 2020 Jul 1;26(13):3397-3407. doi: 10.1158/1078-0432.CCR-19-2786. Epub 2020 Feb 14.
Kollmann, Karoline; Briand, Coralie; Bellutti, Florian; Schicher, Nikolaus; Blunder, Stefan; Zojer, Markus; Hoeller, Christoph;,
The interplay of CDK4 and CDK6 in melanoma, Oncotarget Vol.10, 2019
Le Moigne, R., Aftab, B. T., Djakovic, S., Dhimolea, E., Valle, E., Murnane, M., . . . Rolfe, M. (2017),
The p97 inhibitor CB-5083 is a unique disrupter of protein homeostasis in models of multiple myeloma., Molecular Cancer Therapeutics, 16(11), 2375-2386. doi:10.1158/1535-7163.MCT-17-0233 [doi]
Sukowati, C. H., Anfuso, B., Croce, L. S., & Tiribelli, C. (2015).,
The role of multipotent cancer associated fibroblasts in hepatocarcinogenesi, BMC Cancer, 15, 188-015-1196-y. doi:10.1186/s12885-015-1196-y [doi]
Zhang, X. D., Baladandayuthapani, V., Lin, H., Mulligan, G., Li, B., Esseltine, D. W., . . . Orlowski, R. Z. (2016).,
Tight junction protein 1 modulates proteasome capacity and proteasome inhibitor sensitivity in multiple myeloma via EGFR/JAK1/STAT3 signaling., Cancer Cell, 29(5), 639-652. doi:S1535-6108(16)30109-X [pii]
Alkim E, Dowst H, DiCarlo J, Dobrolecki LE, Hernández-Herrera A, Hormuth DA 2nd, Liao Y, McOwiti A, Pautler R, Rimawi M, Roark A, Srinivasan RR, Virostko J, Zhang B, Zheng F, Rubin DL, Yankeelov TE, Lewis MT.,
Toward Practical Integration of Omic and Imaging Data in Co-Clinical Trials., Tomography. 2023 Apr 10;9(2):810-828. doi: 10.3390/tomography9020066.
Chang G, Shi L, Ye Y, Shi H, Zeng L, Tiwary S, Huse JT, Huo L, Ma L, Ma Y, Zhang S, Zhu J, Xie V, Li P, Han L, He C, Huang S.,
YTHDF3 Induces the Translation of m(6)A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis, Cancer Cell. 2020 Dec 14;38(6):857-871.e7. doi: 10.1016/j.ccell.2020.10.004. Epub 2020 Oct 29.
Kanakkanthara, Arun; Huntoon, Catherine J; Hou, Xiaonan; Zhang, Minzhi; Heinzen, Ethan P; OBrien, Daniel R; Oberg, Ann L; John Weroha, S; Kaufmann, Scott H; Karnitz, Larry M;,
ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer., Nature communications Vol.10, 2019